Evidence map›Paper›PMID 35932032›Full record

ArticleAlzheimer's research & therapy2022

Discovery and validation of dominantly inherited Alzheimer's disease mutations in populations from Latin America.

Leonel Tadao Takada, Carmen Aláez-Verson, Bhagyashri D Burgute, Ricardo Nitrini, Ana Luisa Sosa, Raphael Machado Castilhos, Marcia Fagundes Chaves, Erika-Mariana Longoria, Karol Carrillo-Sánchez, Sonia Maria Dozzi Brucki and 15 more

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Evaluating pathogenicity of variants of unknown significance in APP, PSEN1, and PSEN2.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  8. Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 8 institutions in 4 countries.

Leonel Tadao Takada *Department of Neurology, Hospital das Clinicas, University of São Paulo Medical School, São Paulo, Brazil.
Carmen Aláez-Verson *Laboratorio de Diagnóstico Genómico, Instituto Nacional de Medicina Genómica, Ciudad de México, México.
Bhagyashri D Burgute *Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA.
Ricardo NitriniDepartment of Neurology, Hospital das Clinicas, University of São Paulo Medical School, São Paulo, Brazil.
Ana Luisa SosaInstituto Nacional de Neurología y Neurocirugía, Ciudad de Mexico, Mexico.
Raphael Machado CastilhosNeurology Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Marcia Fagundes ChavesNeurology Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Erika-Mariana LongoriaInstituto Nacional de Neurología y Neurocirugía, Ciudad de Mexico, Mexico.
Karol Carrillo-SánchezLaboratorio de Diagnóstico Genómico, Instituto Nacional de Medicina Genómica, Ciudad de México, México.
Sonia Maria Dozzi BruckiDepartment of Neurology, Hospital das Clinicas, University of São Paulo Medical School, São Paulo, Brazil.
Luis Leonardo Flores-LagunesLaboratorio de Diagnóstico Genómico, Instituto Nacional de Medicina Genómica, Ciudad de México, México.
Carolina MolinaLaboratorio de Diagnóstico Genómico, Instituto Nacional de Medicina Genómica, Ciudad de México, México.
Marcos Jimenez OlivaresLaboratorio de Diagnóstico Genómico, Instituto Nacional de Medicina Genómica, Ciudad de México, México.
Ellen ZiegemeierDepartment of Neurology, Washington University School of Medicine, St Louis, MO, USA.
Jennifer PetranekDepartment of Neurology, Washington University School of Medicine, St Louis, MO, USA.
Alison M GoateDepartment of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Carlos CruchagaDepartment of Psychiatry, Washington University School of Medicine, St Louis, MO, USA.
Alan E RentonDepartment of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Maria Victoria FernándezDepartment of Psychiatry, Washington University School of Medicine, St Louis, MO, USA.
Gregory S DayDepartment of Neurology, Mayo Clinic Florida, Jacksonville, FL, USA.
Eric McDadeDepartment of Neurology, Washington University School of Medicine, St Louis, MO, USA.
Randall J BatemanDepartment of Neurology, Washington University School of Medicine, St Louis, MO, USA.
Celeste M KarchDepartment of Psychiatry, Washington University School of Medicine, St Louis, MO, USA.
Jorge J Llibre-GuerraDepartment of Neurology, Washington University School of Medicine, St Louis, MO, USA. jllibre-guerra@wustl.edu.
Dominantly Inherited Alzheimer Network
Washington University in St. Louis · USHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRInstituto de Medicina Genómica · ESHospital de Clínicas de Porto Alegre · BRIcahn School of Medicine at Mount Sinai · USInstituto Nacional de Neurología y Neurocirugía · MXNational Institute of Genomic Medicine · MXMayo Clinic in Florida · US

Funding

Imaging CoreU19AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2010 to 2025
$53.9M
Understanding Alzheimer disease heterogeneity in Hispanic populations.K01AG073526 · NIA · WASHINGTON UNIVERSITY · PI Jorge Jesus Llibre-Guerra · 2022 to 2026
$511k
NIA NIH HHS K01 AG073526NIA NIH HHS U19 AG032438
6 · The paper itself

Abstract

backgroundIn fewer than 1% of patients, AD is caused by autosomal dominant mutations in either the presenilin 1 (PSEN1), presenilin 2 (PSEN2), or amyloid precursor protein (APP) genes. The full extent of familial AD and frequency of these variants remains understudied in Latin American (LatAm) countries. Due to the rare nature of these variants, determining the pathogenicity of a novel variant in these genes can be challenging. Here, we use a systematic approach to assign the likelihood of pathogenicity in variants from densely affected families in Latin American populations.

methodsClinical data was collected from LatAm families at risk for DIAD. Symptomatic family members were identified and assessed by local clinicians and referred for genetic counseling and testing. To determine the likelihood of pathogenicity among variants of unknown significance from LatAm populations, we report pedigree information, frequency in control populations, in silico predictions, and cell-based models of amyloid-beta ratios.

resultsWe identified five novel variants in the presenilin1 (PSEN1) gene from Brazilian and Mexican families. The mean age at onset in newly identified families was 43.5 years (range 36-54). PSEN1 p.Val103_Ser104delinsGly, p.Lys395Ile, p.Pro264Se, p.Ala275Thr, and p.Ile414Thr variants have not been reported in PubMed, ClinVar, and have not been reported in dominantly inherited AD (DIAD) families. We found that PSEN1 p.Val103_Ser104delinsGly, p.Lys395Ile, p.Pro264Se, and p.Ala275Thr produce Aβ profiles consistent with known AD pathogenic mutations. PSEN1 p.Ile414Thr did not alter Aβ in a manner consistent with a known pathogenic mutation.

conclusionsOur study provides further insights into the genetics of AD in LatAm. Based on our findings, including clinical presentation, imaging, genetic, segregations studies, and cell-based analysis, we propose that PSEN1 p.Val103_Ser104delinsGly, p.Lys395Ile, p.Pro264Se, and p.Ala275Thr are likely pathogenic variants resulting in DIAD, whereas PSEN1 p.Ile414Thr is likely a risk factor. This report is a step forward to improving the inclusion/engagement of LatAm families in research. Family discovery is of great relevance for the region, as new initiatives are underway to extend clinical trials and observational studies to families living with DIAD.

Indexed as

Alzheimer DiseaseAdultAmyloid beta-Protein PrecursorHumansLatin AmericaMiddle AgedMutationPresenilin-1Amyloid beta-Protein PrecursorPresenilin-1Dominantly inherited Alzheimer diseaseEarly-onset Alzheimer diseaseLatin AmericaPresenilin 1

Identifiers

PMID35932032
PMCPMC9354296
OpenAlexW4289889028

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.